Xia et al. Upadacitinib in refractory Behcets. Open label, 8 patients. Follow-up 4-14 months. Lower disease activity 2.5 vs 1.5. Lower pred, 11.9 vs 8.1. @RheumNow #ACR24 Abstr#2515 https://t.co/ZXsJkNRlTm https://t.co/S8LhpqZ8X3

• Upadacitinib for Refractory Behçet’s Syndrome: A Multi-center, Prospective, Ope…
• https://x.com/RichardPAConway/status/1858557782405833156/photo/1

In the horizon for Knee #OA pain management - XG005 - non opioid inhibiting inflammatory and neuropathic signals via the COX enzymes and the calcium subunit. Phase 2b , placebo control, double blind study Abst #L08 #ACR24 @RheumNow https://t.co/j4qkj1Xvbr

• https://x.com/bella_mehta/status/1858558034366304734/photo/1

US biosimilar exp Interchangeable biosimilar - can substitute for reference product wo consulting MD Primary endpt: pharmacokinetic data 61 approved biosimilars @RheumKay: “pts should share in financial benefits” Currently 5-87% discount #PBMReform @ACRheumDC @RheumNow #ACR24 https://t.co/RqwbZalZko

• https://x.com/ericdeinmd/status/1858547083017363622/photo/1
• https://x.com/ericdeinmd/status/1858547083017363622/photo/1
• https://x.com/ericdeinmd/status/1858547083017363622/photo/1

Abstract 1842: Off the shelf CAR T therapy No lymphodepletion needed, delivering robust, targeted CD19+ B cell elimination in multiple in vitro assays @RheumNow #ACR24

If you’re starting with DMARD (according to ACR/VF guidelines) tx in TAK - MTX and AZA are probably equivalent options… MMF not so much @RheumNow #ACR24 https://t.co/jn52ujtspo

• https://x.com/Dr_Brian_MD/status/1858537546902335997/photo/1

Early observational data suggesting JAK inhibitors can play a role in TAK tx We have seen this with UPA in GCA this conference… time for SELECT-TAK ! @RheumNow #ACR24 https://t.co/B2Wa8sOFTp

• https://x.com/Dr_Brian_MD/status/1858538311314235670/photo/1

#ACR24 - Featured Industry Presentations Many of the great presentations for this meeting come from industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.… https://t.co/I6LMQ5xMUx https://t.co/UzTeqWUSdo

Gottenberg et al. A positive RCT in pSS! DAHLIAS study. Phase 2. 163 patients. Nipocalimab, anti-neonatal Fc receptor (FcRn) mAb. @RheumNow #ACR24 Abstr#2527 https://t.co/M7li4ZoKeY https://t.co/gV9MGnswdR

• Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primar…
• https://x.com/RichardPAConway/status/1858513994107297997/photo/1

Nipocalimab, an anti-neonatal Fc receptor (FcRn) mAb, reduces circulating IgG including specific autoantibodies (AAb), by selectively blocking IgG–FcRn interactions. DAHLIAS, the first study of a FcRn blocker in SjD, showed that nipocalimab led to significant improvement vs PBO… https://t.co/zl1tEsEMAj https://t.co/qrkOD2Ccc3

• https://x.com/i/web/status/1858514245820051729
• https://x.com/synovialjoints/status/1858514245820051729/photo/1